IM-01 ANTI-TUMOR EFFECT OF TRASTUZUMAB, GM-CSF AND IL-2 COMBINATORIAL THERAPY IN PEDIATRIC EPENDYMOMA

Documenti analoghi

• EPN-28 GM-CSF IS CRITICAL FOR TRASTUZUMAB EFFICACY IN PEDIATRIC EPENDYMOMA
  di: Donson, Andrew, et al.
  Pubblicazione: (2016)
• IM-08 INFLAMMATION DRIVER, NF-kB, IS ASSOCIATED WITH POOR OUTCOME GROUP A EPENDYMOMA AND REGULATES A KEY IMMUNE SUPPRESSIVE SIGNALING PATHWAY INVOLVED IN THE TUMOR MICROENVIRONMENT
  di: Griesinger, Andrea, et al.
  Pubblicazione: (2015)
• EAPH-14. MOLECULAR BIOLOGY AND PHASE I STUDY OF GM-CSF AND INTRATHECAL TRASTUZUMAB IN CHILDREN WITH RECURRENT POSTERIOR FOSSA EPENDYMOMA
  di: Dorris, Kathleen, et al.
  Pubblicazione: (2018)
• EPCT-18. PHASE 0/I STUDY OF GM-CSF AND INTRATHECAL TRASTUZUMAB IN CHILDREN WITH RECURRENT POSTERIOR FOSSA EPENDYMOMA
  di: Dorris, Kathleen, et al.
  Pubblicazione: (2020)
• EP-04 ACTIVATION OF THE IL6/STAT3 PATHWAY IN CHILDHOOD EPENDYMOMA IS ASSOCIATED WITH A PRO-INFLAMMATORY TUMOR MICROENVIRONMENT AND A POOR PROGNOSIS
  di: Griesinger, Andrea, et al.
  Pubblicazione: (2015)